M-083

Supelco

Methylphenidate hydrochloride solution

ampule of 1 mL, (Racemic mixture), 1.0 mg/mL in methanol (as free base), certified reference material, Cerilliant®

Empirical Formula (Hill Notation):
C14H20ClNO2
CAS Number:
Molecular Weight:
269.77
MDL number:
PubChem Substance ID:
NACRES:
NA.24

Quality Level

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIB (Portugal)

concentration

1.0 mg/mL in methanol (as free base)

application(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Featured Industry

Pharmaceutical (small molecule)

format

single component solution

storage temp.

2-8°C

SMILES string

Cl.COC(=O)C(C1CCCCN1)c2ccccc2

InChI

1S/C14H19NO2.ClH/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12;/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3;1H

InChI key

JUMYIBMBTDDLNG-UHFFFAOYSA-N

Gene Information

General description

Methylphenidate is a psychostimulant prescribed for treatment of attention-deficit hyperactivity disorder (ADHD), tachycardia and narcolepsy. This Certified Spiking Solution® is applicable for use in LC/MS or GC/MS applications for urine drug testing, clinical toxicology and forensic analysis. Methylphenidate is sold under trade names Concerta® and Ritalin®.

Legal Information

CERILLIANT is a registered trademark of Cerilliant Corporation
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Concerta is a registered trademark of ALZA Corporation
Ritalin is a registered trademark of Novartis Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Cerilliant Corporation

Signal Word

Danger

Target Organs

Eyes

RIDADR

UN1230 - class 3 - PG 2 - Methanol, solution

WGK Germany

WGK 1

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Certificate of Analysis

Certificate of Origin

Methylphenidate: trismus.
Prescrire international, 22(140), 185-185 (2013-08-21)
Liv Larsen Stray et al.
Behavioral and brain functions : BBF, 9, 18-18 (2013-05-07)
Most children who are diagnosed with attention deficit-hyperactivity disorder (ADHD) have moderate-to-severe motor problems using the Motor Function Neurological Assessment battery (MFNU). The MFNU focuses on specific muscle adjustment problems associated with ADHD, especially motor inhibition problems and high muscle...
Methylphenidate vs atomoxetine: personalized medicine in attention- deficit/hyperactivity disorder.
Hartmut Heinrich et al.
JAMA psychiatry, 70(5), 545-545 (2013-05-03)
Alice Charach et al.
Pediatrics, 131(5), e1584-e1604 (2013-04-03)
The US Agency for Healthcare Research and Quality sponsored a comparative effectiveness review of interventions for preschoolers at risk for attention-deficit/hyperactivity disorder (ADHD). Medline, Cochrane CENTRAL, Embase, PsycInfo, and Education Resources Information Center were searched from 1980 to November 24...
Sucharita S Somkuwar et al.
Biochemical pharmacology, 86(2), 309-316 (2013-04-30)
Attention deficit/hyperactivity disorder (ADHD) is attributed to dysfunction of the prefrontal cortex. Methylphenidate, an inhibitor of dopamine and norepinephrine transporters (DAT and NET, respectively), is a standard treatment for ADHD. The Spontaneously Hypertensive Rat (SHR) is a well-established animal model...
Articles
As a major metabolite of methylphenidate (1, Ritalin), ±-threo-Ritalinic acid (2) is of clinical relevance.
Read More

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.